CSL plans flu vaccine BLA by 2007
This article was originally published in Pharmaceutical Approvals Monthly
CSL plans to submit a BLA "within 12 months for both multi-dose vial and thimerosal-free single-dose" formulations of an influenza vaccine, the Australian firm announces Feb. 7. A clinical study is slated to begin "later this year." An early 2007 submission could put the CSL flu vaccine on the U.S. market in time for the 2007-2008 season; the firm plans to supply "up to 20 mil. doses to the U.S. as the expanded plant comes online in 2008," CSL says. The company has manufactured flu vaccine in its Melbourne facility since 1968...
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.